Recurrence of hepatocellular carcinoma after liver transplantation: Is immunosuppression a factor?
Authors:
Open Access
- 21 April 2005
- journal article
- editorial
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 11 (5) , 494-496
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: Key role of immunosuppressionLiver Transplantation, 2005
- De Novo Neoplasia After Liver Transplantation: An Analysis of Risk Factors and Influence on SurvivalLiver Transplantation, 2004
- Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinomaLiver Transplantation, 2004
- Mammalian target of rapamycin inhibition as therapy for hematologic malignanciesCancer, 2004
- Recurrence of hepatocellular carcinoma after liver transplant: Patterns and prognosisLiver Transplantation, 2004
- Survival signalling by Akt and eIF4E in oncogenesis and cancer therapyNature, 2004
- Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell CarcinomaJournal of Clinical Oncology, 2004
- Tacrolimus enhances transforming growth factor-β1 expression and promotes tumor progressionTransplantation, 2003
- Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survivalLiver Transplantation, 2003
- The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: A pilot studyHepatology, 1997